Health · September 6, 2026 · 10 min read
Why I Prefer Tirzepatide Over Retatrutide—At Least for Now
Retatrutide has generated excitement for weight loss, but it remains investigational. Learn why I currently prefer FDA-approved tirzepatide, including what we know about efficacy, safety, and retatrutide's potential effect on resting heart rate.
If you've spent any time researching the newest weight-loss medications, you've probably heard people talking about retatrutide, sometimes nicknamed "reta." And I understand the excitement.
Early clinical research on retatrutide has produced impressive weight-loss results. But when someone asks me whether I'd choose retatrutide or tirzepatide today, my answer is straightforward: I prefer tirzepatide.
Not because I think retatrutide is a bad medication. In fact, retatrutide may eventually become an important advancement in obesity medicine. I prefer tirzepatide because we already have an FDA-approved medication with extensive clinical evidence, an established safety profile and real-world clinical experience—while retatrutide is still investigational.
Here's what I think patients should know before getting swept up in the hype.
First, what is tirzepatide?
Tirzepatide is a once-weekly medication that activates two metabolic hormone receptors: GIP + GLP-1. For chronic weight management, tirzepatide is FDA-approved under the brand name Zepbound for appropriate patients.
Its ability to target both GIP and GLP-1 is one reason tirzepatide represented such a major advancement over earlier single-receptor GLP-1 medications. It can reduce appetite, increase feelings of fullness and produce substantial weight loss when combined with appropriate nutrition and lifestyle changes.
And importantly for me, we're no longer talking about an experimental drug. We're talking about a medication that has gone through the FDA approval process and has an established prescribing label describing its indications, contraindications, warnings and adverse reactions.
So what is retatrutide?
Retatrutide takes the concept one step further. It's a triple receptor agonist being developed by Eli Lilly that activates: GIP + GLP-1 + glucagon receptors. That third component—glucagon receptor agonism—is one reason researchers are so interested in it.
And the results so far deserve attention.
In the published Phase 2 obesity trial, participants receiving the highest studied retatrutide dose had an average weight reduction of approximately 24.2% at 48 weeks. That's remarkable.
But remarkable early efficacy doesn't automatically make something my preferred treatment.
Retatrutide is still investigational
This is probably my biggest reason for choosing tirzepatide today.
As of September 2026, retatrutide is not FDA-approved. Lilly explicitly describes it as an investigational medication whose safety and efficacy are still being evaluated. It remains in the Phase 3 clinical-development program.
In fact, researchers are conducting a Phase 3 head-to-head trial comparing retatrutide directly with tirzepatide in adults with obesity. That study has an estimated primary completion in November 2026.
I'm very interested to see those results. But until we have the complete Phase 3 picture and regulatory review, I'm comfortable saying: newer isn't automatically better.
One retatrutide finding I'm watching closely: heart rate
One of the differences I find particularly interesting involves heart rate. In retatrutide's Phase 2 obesity trial, researchers observed dose-dependent increases in heart rate. Heart rate increased through approximately week 24 and subsequently declined later in treatment.
Researchers noted that both glucagon and GLP-1 can exert effects that increase heart rate and cardiac contractility.
The study also reported cardiac arrhythmias among some participants. Most were mild or moderate; one severe prolonged-QT event occurred in a participant who was also taking ondansetron. These findings don't establish that retatrutide causes dangerous cardiovascular outcomes—but they're exactly the kind of safety signals larger and longer Phase 3 studies are designed to clarify.
Tirzepatide isn't completely neutral on heart rate either, and that's important to acknowledge.
FDA prescribing information for Zepbound reports an average increase in heart rate of approximately 1–3 beats per minute in pooled clinical trials compared with no increase in placebo recipients.
So my argument isn't that tirzepatide never affects heart rate. It's that its safety profile is considerably more established because it has completed the clinical and regulatory process necessary for FDA approval.
Retatrutide has other potential side effects too
The most frequently reported adverse effects in the Phase 2 retatrutide study were gastrointestinal—the same general category we're accustomed to discussing with GLP-1-based medications. These included nausea, diarrhea, vomiting and constipation, and they tended to become more common at higher doses. Investigators also reported decreased appetite, fatigue, increased lipase, hypersensitivity reactions, altered skin sensation and other adverse events.
There was also one case of acute pancreatitis in the trial, although a single event doesn't establish causation.
Again, none of this means retatrutide will ultimately prove unsafe. It means we're still learning. And that's precisely why clinical trials exist.
Why I don't recommend buying "reta" online
This deserves its own section because I'm seeing increasing interest in "research" retatrutide being sold online. That's very different from receiving an approved prescription medication through legitimate medical care.
Lilly states that retatrutide is currently legally available only through its clinical trials and specifically warns consumers against products being sold as retatrutide outside those trials because their identity, purity, strength and safety cannot be assured.
For me, potentially losing a little more weight isn't worth gambling on an unapproved product from an uncertain source.
Tirzepatide isn't risk-free either
FDA approval doesn't mean "no side effects." Tirzepatide commonly causes gastrointestinal effects including nausea, diarrhea, vomiting and constipation. Its prescribing information also contains important warnings and contraindications that clinicians need to evaluate before treatment.
That's one reason I believe medical weight loss should actually be medical. It shouldn't simply be about getting access to a vial. It should involve determining whether treatment is appropriate for you, monitoring your response and adjusting your program around your health and goals.
So, could I change my mind about retatrutide?
Absolutely. Science isn't about picking a team and defending it forever.
Retatrutide's early results are exciting, and ongoing Phase 3 studies are investigating it across obesity and several obesity-related conditions.
If those trials confirm exceptional efficacy with an acceptable long-term safety profile and the FDA ultimately approves retatrutide, I'll evaluate the evidence available at that time. But today, I don't think "potentially more powerful" automatically means "better choice."
Why I currently choose tirzepatide
For me, the equation is pretty simple:
Tirzepatide: FDA-approved + highly effective + established dosing + substantially more clinical experience.
Retatrutide: potentially extremely effective + exciting mechanism + promising clinical trials + still investigational and not FDA-approved.
That's why, for appropriate patients, tirzepatide is the option I prefer today.
At Rise Wellness & Longevity, we're not interested in chasing whatever peptide happens to be trending on social media this month. Our goal is to help people make informed decisions about medical weight loss using treatments selected by qualified clinicians based on their health history, goals and the available evidence.
Because successful weight loss isn't about finding the newest molecule. It's about finding the right strategy for you—and building results you can actually maintain.
This article is for educational purposes only and is not medical advice. Medication selection, eligibility and dosing should be determined by a qualified healthcare professional. Retatrutide is investigational and is not FDA-approved as of September 2026.